Valthos, a new biodefense company building AI-driven systems to identify and counter biological threats, has secured $30 million in seed financing. The round was led by the OpenAI Startup Fund, Lux Capital, and Founders Fund, marking one of the largest early-stage investments in the emerging AI biodefense sector. The capital will accelerate development of Valthos’ real-time platforms that analyze biological sequences and design adaptive medical countermeasures for government and life sciences partners.
Co-founded by Kathleen McMahon, formerly head of Palantir’s life sciences division, and Tess van Stekelenburg of Lux Capital, Valthos brings together engineers from Palantir and DeepMind and computational biologists from Stanford’s Arc Institute and MIT’s Broad Institute. With the new funding, the company plans to scale its software infrastructure and expand its engineering organization to support both commercial and government biodefense programs.
